S udden cardiac arrest (SCA) and sudden cardiac death (SCD) are disastrous outcomes of various predominant cardiac diseases. The leading cause of SCA and SCD is coronary artery disease. 1 However, SCA/SCD in young patients is mainly caused by congenital disorders of primary arrhythmic or structural origin. 2 SCD is defined as death from an unexpected circulatory arrest, usually because of a cardiac arrhythmia occurring within an hour of the onset of symptoms. The definition of SCA is similar, with the addition that a medical intervention (eg, defibrillation) reverses the event. 3 Idiopathic ventricular fibrillation (IVF) is a rare cause of SCA. Patients with IVF present with a sudden onset of ventricular fibrillation (VF) of unknown origin that is not identified even after extensive diagnostic testing. The exact incidence of IVF is unknown but is declining with the advance of diagnostic testing and the discovery of primary arrhythmia syndromes, such as the Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), long-QT syndrome (LQTS), short-QT syndrome, and early repolarization syndrome (ERS).
Although the exact definition of IVF has changed during the years and although new diagnostic tools are available, no specific guidelines have been developed for the definition and diagnosis of IVF, as well as a protocol for exclusion of specific cardiac diseases that cause SCA and SCD. In this review, we discuss the definition of IVF, overlap with other primary arrhythmia syndromes, the diagnosis, and follow-up of patients with IVF.
Definition of IVF and Overlap With Other Primary Arrhythmia Syndromes
Two different consensus statements about IVF have been published, and proposed 2 different definitions of IVF. The first is from the 1997 Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and the United States that describes IVF as the terminology that best acknowledges our current inability to identify a causal relationship between the clinical circumstance and the arrhythmia. 4 The second and more recent definition is from the 2013 Heart Rhythm Society/European Heart Rhythm Association/ Asia Pacific Heart Rhythm Society expert consensus statement of inherited primary arrhythmia syndromes and defines IVF as a resuscitated cardiac arrest victim, preferably with documentation of VF, in whom known cardiac, respiratory, metabolic and toxicological causes have been excluded through clinical evaluation. 5 In other words, the diagnosis IVF depends on the absence of a substrate for VF and exclusion of specific diseases, including structural cardiac disease (ie, myocarditis, cardiac sarcoidosis, arrhythmogenic right ventricular, hypertrophic, and dilated cardiomyopathy) and primary arrhythmia syndromes (ie, BrS, CPVT, LQTS, short-QT syndrome, and ERS).
Most primary arrhythmia disorders were regarded as IVF before they were discovered. For example, BrS was described as IVF in a 1998 Nature article. 6 Studies in which careful phenotypic and genetic analysis had been performed showed that these primary arrhythmia syndromes are actually separate disease entities, with a separate pathophysiology. 7, 8 The differentiation between IVF and other primary arrhythmic syndromes has been facilitated by the advance in genetic testing, for example in CPVT and LQTS patients where the yield of genetic testing is 60% and 75%, respectively. 9 In addition, genetic testing has facilitated the detection of causative mutations for IVF, such as the Dutch DPP6-haplotype and CALM1. 10, 11 Early repolarization (ER) is a common electrocardiographic finding that is present in 1% to 5% of the general population. 12 ER pattern is defined as J-point elevation of ≥0.1 mV in ≥2 contiguous leads of a standard 12-lead ECG, excluding leads V1-V3, with an end-QRS notch or slur on the downslope of the R wave with an onset above the baseline. 5, 13 Although ER historically was regarded as a benign finding, multiple studies have shown that ER, and specifically ER in the inferior and lateral leads is associated with an increased risk of VF and SCD. 14 ER pattern is differentiated from ERS, that is diagnosed in patients with unexplained VF or polymorphic VT and documented ER, or in SCD victims with a negative autopsy and a previous ECG demonstrating ER. 5 Until recently, ERS was regarded as a subentity of IVF. However, ERS has a distinctive phenotype and has shown to have a separate genetic substrate as several candidate genes for a IVF: Definition, Diagnosis, and Follow-Up familial inheritance of a malign ER pattern have been identified. 15 Therefore, ERS is considered a separate disease entity that is distinct from IVF. If a patient shows ER that does not fulfill the criteria as mentioned above than these abnormalities are not explanatory and the diagnosis IVF remains.
Short-coupled ventricular premature beats (VPBs) may elicit Torsades de Pointes (TdP) or immediate VF. 16 A subgroup of IVF patients show short-coupled VPBs causing TdP/ VF. In these patients, mapping and ablation proved effective to prevent recurrence of short coupled TdP (scTdP)/VF. 17, 18 The pathogenesis of short-coupled VPBs is largely unknown, although a genetic origin is detected in a limited number of patients with scTdP/VF including the Dutch DPP6-haplotype, a novel RyR mutation that causes scTdP in rest, and a novel IRX3 mutation. 10, 19, 20 Until the pathogenesis is further specified, scTdP/VF remains a subgroup of IVF because no particular phenotype responsible for VF can be detected either on the ECG nor during additional diagnostic testing.
Concerning IVF: when do we classify VF as idiopathic? This is a matter of opinion and open for discussion. In fact, here we publish not a consensus document but a personal opinion that incites debate. In our definition of IVF, we have made a distinction between pathogeneses with a clear (sometimes provoked) phenotype, such as LQTS (nonidiopathic) and those without such an obvious phenotype (idiopathic): for example, CALM1 and DPP6 mutations that are still associated with an unclear phenotype. Future research will possibly link these particular mutations to separate disease entities as happened with BrS and other diagnoses ( Figure 1 ).
Pathophysiological Mechanism of IVF and Overlap With Other Arrhythmia Syndromes
The exact pathogenesis and pathophysiological mechanism of IVF are unknown. We hypothesize that IVF has a heterogeneous pathogenesis that is different for each patient with IVF. First, IVF might have a monogenic origin. 10, 19, 20 Second, the origin could be polygenic. Third, the origin might be multifactorial in which mono-or polygenic mutations need particular environmental and discrete subclinical structural abnormalities, for example minimal electrolyte disturbances such as a mild hypokalemia or development of small areas of fibrotic myocardial tissue, that are currently undetectable with the available diagnostic modalities. The monogenic hypothesis (ie, the hypothesis that the disease is caused by 1 gene mutation) is supported by the detection of several causative mutations in patients with IVF, including DPP6, CALM1, the novel RyR2 mutation, and IRX3. 10, 11, 19, 20 The detection of candidate genes for IVF has been accelerated by the advance in genetic testing and the greater availability of new techniques, such as whole-exome or whole-genome sequencing. However, these extensive genetic data need a critical appraisal against the background, genetic noise rate, as many variants of uncertain clinical significance are concurrently detected. In addition, functional studies have to further elucidate the underlying mechanism that translates novel candidate genes into arrhythmogenesis. Although the monogenic hypothesis is supported by the available literature, the polygenic hypothesis (ie, the hypothesis that the disease is caused by ≥2 gene mutations) and the second hit hypothesis (ie, the hypothesis that the disease is the result of accumulated mutations to the cell's DNA) cannot be rejected, as no research has been conducted in these areas.
The pathogenic mutations that are described in inherited primary arrhythmia syndromes and IVF cause changes in the cardiac ion channels. This results in altered ion currents disrupting the normal cardiac action potential morphology. Potentially, any change in action potential morphology might lead to enhanced arrhythmogenesis. 9 Figure 1 . Schematic illustration of the evolution of the diagnosis idiopathic ventricular fibrillation (IVF). In the 2013 Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society expert consensus, statement on the diagnosis of patients with inherited primary arrhythmia syndromes early repolarization syndrome was for the first time mentioned as a separate disease entity. 5 CALM1 indicates calmodulin 1 gene mutation; CPVT, catecholaminergic polymorphic ventricular tachycardia; and DPP6, Dutch DPP6 risk haplotype associated with sudden cardiac death. IVF: Definition, Diagnosis, and Follow-Up
The cellular mechanism of short-coupled VPBs and scTdP is dependent on the transient outward potassium (K + ) current (also known as I to ) of the His and Purkinje fibers. An increase in I to causes a deeper phase 1 of the cardiac action potential. Because the I to only increases in the Purkinje fibers, a strong local repolarization gradient is created with the adjacent ventricular myocardium that results in local ectopy and short-coupled VPBs. VPBs with a short-coupled interval (ie, R-on-T phenomenon) can cause phase 2 reentry and hereby elicit VF. 16 
Differential Diagnosis of Patients With VF
VF has an extensive differential diagnosis consisting of many cardiac and noncardiac causes. As the definition of IVF implies, structural cardiac, primary arrhythmic, respiratory, metabolic, and toxicological causes must be excluded before IVF is diagnosed. Because noncardiac causes of VF are usually easily detected by simple laboratory and toxicological assessment, we exclusively discuss the potential cardiac causes of VF. Table 1 shows, if known, an overview of the incidence and prevalence of the diseases in the cardiac differential diagnosis 
Diagnosis of IVF
The correct diagnosis of IVF requires extensive diagnostic testing. Routine testing excludes the most common causes of VF. Routine testing usually comprises blood chemistry (cardiac enzymes, electrolytes, and thyroid function), toxicological screening, ECG, chest x-ray, echocardiography, exercise testing, Holter or telemetry monitoring, coronary angiography with or without ventriculography, and magnetic resonance imaging. In young patients (<45 years) with a low risk for coronary artery disease, coronary CT or MR angiography is an alternative for coronary angiography because the sensitivity, specificity, and especially the negative predictive value are high. 41, 42 If coronary CT or MR is normal, coronary angiography is not necessary. The mandatory additional diagnostic tests are ergonovine or acetylcholine provocation to exclude coronary artery spasm and administration of a sodium channel blocker (ajmaline, flecainide, procainamide, or pilsicainide) to exclude BrS. Optional additional diagnostic tests are endomyocardial biopsy and electrophysiological testing. In daily practice, the option of additional testing often provokes discussion because the diagnostic value of some additional tests is debatable. Table 2 shows the diagnostic value of the additional provocation tests, specified per disease.
Genetic testing increasingly contributes in diagnosing concealed primary arrhythmia syndromes. The role of extensive genetic testing is, however, controversial in patients with IVF. 5 Targeted genetic screening based on phenotype is performed in a limited number of patients with IVF and the yield is heterogeneous. In addition, variants of uncertain clinical significance are frequently detected. Table 3 shows the yield of genetic testing in patients with IVF.
In summary, acetylcholine and ergonovine have a comparable sensitivity in diagnosing coronary artery spasm. 43, 44 Coronary artery spasm provocation has a potential risk of arrhythmias; however, this risk is acceptable with an overall incidence of ≈5% of arrhythmic complications that can usually be treated adequately. 61, 62 The value of diagnosing coronary artery spasm and the subsequent medical treatment and prevention of ischemic and important arrhythmic events outweighs, in our opinion, the risks of the test.
Of the sodium channel blockers, ajmaline and flecainide show a comparable sensitivity in diagnosing BrS; however, when compared to each other flecainide fails to identify 32% of the patients with BrS. [45] [46] [47] 63 The exact sensitivity of pilsicainide and procainamide is unknown, but all sodium channel blockers are suitable to diagnose BrS. The choice of sodium channel blocker depends on the availability and differs per country.
Although epinephrine shows a high sensitivity and specificity in diagnosing LQTS, healthy subjects show a high number of false-positive test results. 64 Therefore, the epinephrine test is of no additive value in the regular evaluation of LQTS. A good alternative is the highly sensitive QTc posture test, in which QT prolongation is provoked by brisk standing. 55, 56 Epinephrine provocation testing is also not suitable for diagnosing CPVT because of the low sensitivity and specificity. 57 Genetic screening is performed in a limited number of patients, and the yield is heterogeneous. 17, 18, 34, 60 We recommend genetic screening in IVF patients with a negative phenotype with a basic panel of SCN5A and the most common LQTS genes (KCNQ1 and KCNH2), as half of the patients with BrS who present with SCA have a concealed phenotype, and ≈25% of genotype-positive LQTS patients have a normal QT-interval. 30, 65 If a patient presents with exercise-or emotioninduced VF, we recommend additional screening of RyR2 and CALM1. Genetic testing is a matter of debate, and caution is warranted as a negative genetic test result does neither exclude concealed primary arrhythmia syndromes nor a genetic origin of IVF. Although the limited available data on targeted exome sequencing of large gene panels in SCD victims <50 years of age show a yield of 21% to 32%, it is not routinely recommended because the finding of variants of unknown clinical significance may lead to unnecessary treatment and anxiety among patients. [66] [67] [68] 
Characteristics and Follow-Up of Patients With IVF
Multiple studies that focused on IVF have been published; however, data on the diagnosis and follow-up of patients with IVF are limited. 17, 18, 35 Only one study shows the long-term follow-up of 200 patients with an apparently unexplained cardiac arrest and no evident cardiac disease as cause of the cardiac arrest. 34 The other available data on the follow-up of patients with IVF are derived from cohort studies, mostly published before the introduction of magnetic resonance imaging, and report largely incomplete diagnostic data ( Figure 2 ). Structural cardiac diseases and primary arrhythmia syndromes were not systematically excluded; therefore, these cohorts are presumably confounded with patients with unrecognized underlying disease. Nevertheless, these are the best available data on the diagnosis and follow-up of patients with IVF. Table 4 shows the characteristics of these cohorts.
ICD Therapy in Patients With IVF
The only therapeutic option in patients with IVF is secondary prevention with a prophylactic implantable cardiac defibrillator (ICD). ICD implantation in patients with IVF is justified by the high recurrence rate of ventricular arrhythmias, varying from 11% to 45%. 34, 39, 40 A meta-analysis showed recurrences of arrhythmias in 31% of the patients with IVF during a mean follow-up of 5.3 years. 40 Another study showed appropriate ICD therapy in 43% in a median follow-up of 8.8 years, but also included patients with ERS. 39 A recent study showed a lower rate of appropriate ICD therapy: 11% of patients with IVF received one or multiple appropriate shocks in a mean followup of 3.2 years, with a median time to first shock of 2.6 years. 34 No predictors for appropriate ICD therapy have been identified in patients with IVF, although patients with ERS show higher recurrence of ventricular arrhythmias. 39 The limited available data on inappropriate ICD therapy show a high rate of inappropriate shocks (14% to 44%; mean follow-up, 1.9-8.8 years). 34, 39, 70 The reason for most inappropriate shocks is atrial fibrillation. The limited data on ICD complications show complications in 17% in a mean follow-up of 41±27 months. 70 IVF: Definition, Diagnosis, and Follow-Up 
Necessity of Follow-Up and Reassessment of Diagnosis
Today, only 7% of patients reveal a specific diagnosis during follow-up because of comprehensive advanced testing at time of the index event. 34 However, historically almost 30% of patients initially diagnosed with IVF qualify for a specific diagnosis during follow-up. This emphasizes the need for follow-up as in current daily practice many patients were diagnosed with IVF after limited diagnostic testing. 69, 70 The first explanation that many patients qualify for a specific disease is that structural or electric abnormalities were (clinically) absent at time of the index event and developed during follow-up. The second explanation is that the relatively new diagnoses such as BrS were not recognized or described yet at the time of the index event. BrS was first described in 1992, before then patients with BrS were incorrectly regarded as patients with IVF. 7 The third explanation is that development of diagnostic techniques have improved the early detection of specific diseases. High-resolution imaging modalities such as magnetic resonance imaging have been introduced, enhanced the detection of small structural abnormalities, and facilitated diagnosing early-stage cardiomyopathy. New provocation tests and disease algorithms for concealed primary arrhythmia syndromes have been developed, for example ajmaline provocation for the exclusion of BrS and the 1993 Schwartz criteria for LQTS. Genetic testing has become increasingly available and contributed in the early diagnosis of concealed primary arrhythmia syndromes.
The consensus statements provide no or limited advice on the follow-up of patients with IVF. The only advice on follow-up was provided in the 1997 IVF consensus statement that recommended ECG, Holter monitoring, and echocardiograms to be repeated every year. 4 We recommend follow-up of patients with IVF because a third of patients initially diagnosed with IVF reveal a specific disease during follow-up. Diagnosis of a specific disease generally requires lifestyle Guidelines provide limited guidance in the diagnosis and follow-up of patients with IVF; therefore, a protocol is required. A protocol as shown in Figure 3 may be suggested.
Future Perspectives
The incidence of IVF is declining and we expect the number of patients with IVF to decline further. This decline might be explained by the detection of new well-defined primary arrhythmia syndromes, the improvement in high resolution imaging modalities, and the advance in genetic testing. Historically, after limited diagnostic testing all VF patients with an apparently normal heart were diagnosed with IVF, resulting in a heterogeneous and comprehensive group of patients with IVF. Today, IVF is redefined as a rare primary arrhythmia syndrome of unknown, maybe (mono-or poly-) genetic origin that shows different manifestations including scTdP, which however are not explanatory for the arrhythmic event. Genetic testing including the screening of large multigene panels and exome or genome sequencing, followed by functional studies, might redefine IVF even further in the future.
In the present expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes, extensive genetic testing is not recommended in patients with IVF because of the low yield and high costs. 5 However, the costs of genetic testing have decreased, resulting in an increase in the feasibility of genetic testing. Consequently, large custom multigene panels have been created and are rapidly replacing targeted genetic screening based on phenotype. However, the yield of these custom multigene panels has yet to be determined. Moreover, an increasing number of variants of uncertain clinical significance are detected. The interpretation and clinical use of these variants of uncertain clinical significance is challenging. Future research, and more specifically functional studies, have to demonstrate the causality between variants of uncertain clinical significance and IVF.
Conclusions
The diagnosis of IVF depends on exclusion of cardiac, respiratory, metabolic, and toxicological causes. Differentiation from structural cardiac disease and other primary arrhythmia syndromes is critical for targeted therapy, follow-up, and family screening. The present expert consensus statements provide limited guidance on the diagnosis and follow-up of patients with IVF. Therefore, we proposed a protocol for the diagnosis and follow-up of IVF. Follow-up is of utmost importance because ≤30% of patients initially diagnosed with IVF qualify for a specific disease during follow-up. Reassessment of diagnosis is, therefore, always necessary in patients with IVF.
Disclosures
None. The sensitivity is 85% and 99%, respectively, the specificity is 90% and 64%, respectively, the positive predictive value is 91% and 86%, respectively, and the negative predictive value is 83% and 90%, respectively. 41, 42 Coronary CT angiography has a higher sensitivity compared with magnetic resonance imaging (MRI) in detecting coronary stenosis; therefore, CT is a better alternative for coronary angiography. 74 †A proposed acquisition protocol for cardiac MRI is available in the Data Supplement and is based on the arrhythmogenic right ventricular dysplasia/cardiomyopathy protocol. ‡Proposed genetic testing consists of a basic panel of SCN5A, the most common long-QT genes (KCNQ1 and KCNH2), RyR2, and CALM1 in patients with exercise-induced VF. In patients with a negative phenotype, we recommend SCN5A, KCNQ1, and KCNH2 screening. FU indicates follow-up. IVF: Definition, Diagnosis, and Follow-Up
